Appendix 1—table 4. Test for a linear relationship between drug-related effects on model-parameters and DA baseline.

	R²		ß1 estimate		ß1p-value
	sEBR	WMC	sEBR	WMC	sEBR	WMC
$\beta$ (P-D)	2.13e−5	1.52e−3	4.75e−05	2.25e−03	.98	.84
$\phi$ (P-D)	1.87e−2	4.25e−2	1.40e−02	−1.19e−01	.46	.27
$\rho$ (P-D)	5.91e-3	2.42e-3	−4.89e−03	−1.76e−01	.68	.79
$\beta$ (P-H)	2.47e−2	2.93e−2	1.64e−03	1.01e−02	.40	.36
$\phi$ (P-H)	9.58e−3	3.36e−2	−1.01e−02	−1.06e−01	.60	.32
$\rho$ (P-H)	4.61e−2	1.18e−2	−9.01e−03	−2.57e−01	.25	.56
$\beta$ (D-H)	1.57e−3	7.83e−3	1.57e−03	7.83e−03	.43	.49
$\phi$ (D-H)	1.02e−3	2.95e−4	−3.93e−03	1.20e−02	.86	.93
$\rho$ (D-H)	4.11e-3	5.69e-4	−4.07e−02	−8.54e−02	.73	.90

Note. Drug-related differences (P: placebo, D: L-dopa, H: haloperidol) of model parameters for all participants (n = 31). Baseline dopamine (DA) function was assessed by the two behavioral DA proxies spontaneous eye blink rate (sEBR) and working memory capacity (WMC). For the latter, the first principal component across three different WMC tasks was used, denoted by WMCPCA. The column ‘R²’ denotes the R²-values of the linear regressions. The columns ‘β1 estimate’ and ‘β1 p-value’ show for each linear model the estimated value and p-value of the β1 regression coefficient, respectively. β: softmax parameter; φ: exploration bonus parameter; ρ: perseveration bonus parameter.